Moxalactam therapy for neonatal meningitis due to gram-negative enteric bacilli. A prospective controlled evaluation

G. H. McCracken, N. Threlkeld, S. Mize, C. J. Baker, S. L. Kaplan, I. Faingezicht, W. E. Feldman, U. Schaad

Research output: Contribution to journalArticle

Abstract

Moxalactam and ampicillin sodium therapy were compared with amikacin sulfate and ampicillin therapy for meningitis due to gram-negative enteric bacilli in 63 infants enrolled in the Third Neonatal Meningitis Cooperative Study. The population characteristics and causative organisms were comparable for the two treatment groups. Cultures of CSF were positive for approximately three days in both study groups. Case-fatality rates were 23% and 15% for moxalactam-treated infants and ampicillin- and amikacin-treated infants, respectively. Developmental or neurological abnormalities were found in about 40% of survivors, and the rates were comparable for both treatment groups. Computed tomograms in 44 infants were interpreted as normal in 13 (30%); hydrocephalus, abscesses, and low-density areas were the most frequent abnormalities. We conclude that moxalactam is a suitable alternative for treatment of meningitis due to gram-negative enteric bacilli.

Original languageEnglish (US)
Pages (from-to)1427-1432
Number of pages6
JournalJournal of the American Medical Association
Volume252
Issue number11
DOIs
StatePublished - 1984

Fingerprint

Moxalactam
Meningitis
Bacillus
Ampicillin
Amikacin
Therapeutics
Population Characteristics
Hydrocephalus
Abscess
Survivors
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Moxalactam therapy for neonatal meningitis due to gram-negative enteric bacilli. A prospective controlled evaluation. / McCracken, G. H.; Threlkeld, N.; Mize, S.; Baker, C. J.; Kaplan, S. L.; Faingezicht, I.; Feldman, W. E.; Schaad, U.

In: Journal of the American Medical Association, Vol. 252, No. 11, 1984, p. 1427-1432.

Research output: Contribution to journalArticle

McCracken, G. H. ; Threlkeld, N. ; Mize, S. ; Baker, C. J. ; Kaplan, S. L. ; Faingezicht, I. ; Feldman, W. E. ; Schaad, U. / Moxalactam therapy for neonatal meningitis due to gram-negative enteric bacilli. A prospective controlled evaluation. In: Journal of the American Medical Association. 1984 ; Vol. 252, No. 11. pp. 1427-1432.
@article{e4f8ebd8cf0348ad9c0ea46219b43390,
title = "Moxalactam therapy for neonatal meningitis due to gram-negative enteric bacilli. A prospective controlled evaluation",
abstract = "Moxalactam and ampicillin sodium therapy were compared with amikacin sulfate and ampicillin therapy for meningitis due to gram-negative enteric bacilli in 63 infants enrolled in the Third Neonatal Meningitis Cooperative Study. The population characteristics and causative organisms were comparable for the two treatment groups. Cultures of CSF were positive for approximately three days in both study groups. Case-fatality rates were 23{\%} and 15{\%} for moxalactam-treated infants and ampicillin- and amikacin-treated infants, respectively. Developmental or neurological abnormalities were found in about 40{\%} of survivors, and the rates were comparable for both treatment groups. Computed tomograms in 44 infants were interpreted as normal in 13 (30{\%}); hydrocephalus, abscesses, and low-density areas were the most frequent abnormalities. We conclude that moxalactam is a suitable alternative for treatment of meningitis due to gram-negative enteric bacilli.",
author = "McCracken, {G. H.} and N. Threlkeld and S. Mize and Baker, {C. J.} and Kaplan, {S. L.} and I. Faingezicht and Feldman, {W. E.} and U. Schaad",
year = "1984",
doi = "10.1001/jama.252.11.1427",
language = "English (US)",
volume = "252",
pages = "1427--1432",
journal = "JAMA - Journal of the American Medical Association",
issn = "0098-7484",
publisher = "American Medical Association",
number = "11",

}

TY - JOUR

T1 - Moxalactam therapy for neonatal meningitis due to gram-negative enteric bacilli. A prospective controlled evaluation

AU - McCracken, G. H.

AU - Threlkeld, N.

AU - Mize, S.

AU - Baker, C. J.

AU - Kaplan, S. L.

AU - Faingezicht, I.

AU - Feldman, W. E.

AU - Schaad, U.

PY - 1984

Y1 - 1984

N2 - Moxalactam and ampicillin sodium therapy were compared with amikacin sulfate and ampicillin therapy for meningitis due to gram-negative enteric bacilli in 63 infants enrolled in the Third Neonatal Meningitis Cooperative Study. The population characteristics and causative organisms were comparable for the two treatment groups. Cultures of CSF were positive for approximately three days in both study groups. Case-fatality rates were 23% and 15% for moxalactam-treated infants and ampicillin- and amikacin-treated infants, respectively. Developmental or neurological abnormalities were found in about 40% of survivors, and the rates were comparable for both treatment groups. Computed tomograms in 44 infants were interpreted as normal in 13 (30%); hydrocephalus, abscesses, and low-density areas were the most frequent abnormalities. We conclude that moxalactam is a suitable alternative for treatment of meningitis due to gram-negative enteric bacilli.

AB - Moxalactam and ampicillin sodium therapy were compared with amikacin sulfate and ampicillin therapy for meningitis due to gram-negative enteric bacilli in 63 infants enrolled in the Third Neonatal Meningitis Cooperative Study. The population characteristics and causative organisms were comparable for the two treatment groups. Cultures of CSF were positive for approximately three days in both study groups. Case-fatality rates were 23% and 15% for moxalactam-treated infants and ampicillin- and amikacin-treated infants, respectively. Developmental or neurological abnormalities were found in about 40% of survivors, and the rates were comparable for both treatment groups. Computed tomograms in 44 infants were interpreted as normal in 13 (30%); hydrocephalus, abscesses, and low-density areas were the most frequent abnormalities. We conclude that moxalactam is a suitable alternative for treatment of meningitis due to gram-negative enteric bacilli.

UR - http://www.scopus.com/inward/record.url?scp=0021185938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021185938&partnerID=8YFLogxK

U2 - 10.1001/jama.252.11.1427

DO - 10.1001/jama.252.11.1427

M3 - Article

C2 - 6381775

VL - 252

SP - 1427

EP - 1432

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0098-7484

IS - 11

ER -